Researchers say tocilizumab could also help patients on general wards and relieve pressure on NHS
A rheumatoid arthritis drug previously found to save lives among intensive care patients with Covid could also help those receiving oxygen on general wards and reduce pressure on the NHS, researchers have found.
A trial called Remap-Cap revealed last month that the anti-inflammatory drug tocilizumab cut both the risk of death among Covid patients in intensive care and the length of time patients spent in such units.
